GlobalData on MSN3d
Lundbeck gains FDA fast track designation for MSA therapy amlenetug
Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...
Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).
H. Lundbeck A/S: Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).
Contract Pharma3d
Lundbeck’s Potential Treatment for Multiple System Atrophy Granted Fast Track Designation
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).
PharmaTimes3d
Amlenetug receives FDA Fast Track Designation
Amlenetug received Orphan Drug Designation (ODD) from the US FDA in April 2024, the EMA in May 2021 and SAKIGAKE designation ...
Lundbeck's covert mission to help bring home kidnapped psychiatrist Keith Siegel
Recognizing Siegel’s importance as an employee and a respected figure among Israeli psychiatrists, Lundbeck Global took ...
Le Lézard3d
Global Times: How Nanyang's mugwort industry empowers 300,000 farmers on path to poverty alleviation and prosperity
Festival holidays wind down, the production line at Nanyang Yaoyibao Mugwort Products Company (hereafter as Yaoyibao Company) in Nanyang, Central China's Henan Province, roars back to life. The air ...
Alpha-Synuclein Inhibitors Clinical Trial Pipeline As Novel And Extensive 22+ Therapies Likely To Enter In The Domain | Delveinsight
Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...
pharmaphorum1d
Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...
Medscape4d
Underfunded, Underdiagnosed, and Misunderstood: What’s Next for Bipolar Disorder
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.